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Abstract
Background: Retinoid X receptor (RXR) c is a nuclear receptor-type transcription factor expressed mostly in skeletal muscle,
and regulated by nutritional conditions. Previously, we established transgenic mice overexpressing RXRc in skeletal muscle
(RXRc mice), which showed lower blood glucose than the control mice. Here we investigated their glucose metabolism.
Methodology/Principal Findings: RXRc mice were subjected to glucose and insulin tolerance tests, and glucose transporter
expression levels, hyperinsulinemic-euglycemic clamp and glucose uptake were analyzed. Microarray and bioinformatics
analyses were done. The glucose tolerance test revealed higher glucose disposal in RXRc mice than in control mice, but
insulin tolerance test revealed no difference in the insulin-induced hypoglycemic response. In the hyperinsulinemic-
euglycemic clamp study, the basal glucose disposal rate was higher in RXRc mice than in control mice, indicating an insulin-
independent increase in glucose uptake. There was no difference in the rate of glucose infusion needed to maintain
euglycemia (glucose infusion rate) between the RXRc and control mice, which is consistent with the result of the insulin
tolerance test. Skeletal muscle from RXRc mice showed increased Glut1 expression, with increased glucose uptake, in an
insulin-independent manner. Moreover, we performed in vivo luciferase reporter analysis using Glut1 promoter (Glut1-Luc).
Combination of RXRc and PPARd resulted in an increase in Glut1-Luc activity in skeletal muscle in vivo. Microarray data
showed that RXRc overexpression increased a diverse set of genes, including glucose metabolism genes, whose promoter
contained putative PPAR-binding motifs.
Conclusions/Significance: Systemic glucose metabolism was increased in transgenic mice overexpressing RXRc. The
enhanced glucose tolerance in RXRc mice may be mediated at least in part by increased Glut1 in skeletal muscle. These
results show the importance of skeletal muscle gene regulation in systemic glucose metabolism. Increasing RXRc expression
may be a novel therapeutic strategy against type 2 diabetes.
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Introduction
The skeletal muscle, known as the largest organ in the human
body, plays an important role in exercise, energy expenditure, and
glucose metabolism. It is a major site of glucose disposal [1,2]. In
type 2 diabetic subjects, glucose uptake in the skeletal muscle is
impaired [2]. Blood glucose is taken up by the skeletal muscle via
insulin-dependent and independent glucose transporters (Glut4
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20467and Glut1, respectively) [3], where it is converted into glycogen.
Increasing capacity of glucose uptake in the skeletal muscle is
considered beneficial for the prevention and treatment of type 2
diabetes [3,4]. On the other hand, glucose metabolism in the
skeletal muscle may affect the whole body metabolism; the skeletal
muscle-specific inactivation of Glut4 has resulted in defect in
insulin action in the adipose tissue (glucose uptake) and liver
(suppression of gluconeogenesis) [5]. Thus, identification of the
molecular mechanisms involved in skeletal muscle glucose
metabolism should help clarify the pathophysiology of diabetes.
Nuclear receptors are part of a large superfamily of transcrip-
tion factors that includes receptors for steroids, retinoic acid, and
thyroid hormones [6]. RXRs are heterodimeric partners of many
nuclear receptors, such as retinoic acid receptors (RARs), thyroid
hormone receptors (T3Rs), liver X receptors (LXRs), peroxisome
proliferator activated receptors (PPARs), and RXRs themselves
[6]. Among RXR heterodimer partners, activation of PPARd in
the skeletal muscle increases insulin sensitivity [7]. The RXR
subfamily consists of RXRa, RXRb, and RXRc [6,8]. Although
RXRc is preferentially expressed in the skeletal muscle, its
functional role is poorly understood. We have recently found that
expression of retinoid X receptor c (RXRc) is changed in the
skeletal muscle under nutritional conditions; RXRc mRNA
expression is down-regulated by fasting and recovered by
refeeding [9]. In an attempt to explore the role of RXRc in the
skeletal muscle, we established transgenic mice overexpressing
RXRc in the skeletal muscle (RXRc mice) and found that they
exhibit increased triglyceride contents in the skeletal muscle as a
result of increased expression of sterol regulatory element binding
protein 1c (SREBP1c), a transcriptional master regulator of
lipogenesis [9]. Indeed, RXRc has been shown to enhance
SREBP1c gene expression in C2C12 myocytes in vitro at least in
part by heterodimerization with LXR [9]. On the other hand, we
also found that blood glucose levels are lower in RXRc mice than
in control mice [9]. These observations, taken together, suggest
that RXRc plays a critical role in glucose and lipid metabolism in
the skeletal muscle. However, the molecular mechanism involved
in RXRc regulation of glucose metabolism in the skeletal muscle
and how it affects systemic glucose metabolism are poorly
understood.
Here, we demonstrate enhanced glucose metabolism with
increased Glut1 expression and glucose uptake in RXRc mice.
This study suggests that activation of the skeletal muscle RXRc is
a novel therapeutic strategy to treat or prevent type 2 diabetes.
Methods
Animals
C57BL6 mice were purchased from Charles River Japan
(Yokohama, Japan). Generation of RXRc mice under the control
of the human a-actin promoter was described previously [9]. They
were allowed free access to food (CRF-1; Charles River) and water,
unless otherwise stated. All animal experiments were approved by
Institutional Animal Care and Use Committee of Tokyo Medical
and Dental University (approval ID: No. 0090041).
Blood analysis
Serum samples were obtained from mice, when fed ad libitum.
Serum glucose levels were measured by the blood glucose test
meter (Glutest PRO R; Sanwa-Kagaku, Nagoya, Japan). Serum
concentrations of insulin were determined by the enzyme-linked
immunosorbent assay (ELISA) kits (Morinaga Institute of
Biological Science, Inc., Yokohama, Japan).
Glucose and insulin tolerance tests
For glucose tolerance test, D-glucose (1 mg/g of body weight,
10% (w/v) glucose solution) was administered by intraperitoneal
injection after an overnight fast. For insulin tolerance test, human
insulin (Humulin R; Eli Lilly Japan K.K., Kobe, Japan) was
injected intraperitoneally (0.75 mU/g of body weight), when fed
ad libitum.
Hyperinsulinemic-euglycemic clamp studies
We analyzed as described previously [10–12] with slight
modification. Two days before the clamp studies, a catheter was
inserted into the right jugular vein for infusion under general
anesthesia with sodium pentobarbital. Studies were performed on
miceunder conscious and unstressed conditions after a 4-hfast. The
clamp study began with a prime (4 mg/kg for 5 min) of [6,6-
2H]
glucose (Cambridge Isotope Laboratories, Inc, Andover, MA)
followed by continuous infusion at a rate of 0.5 mg/kg per minute
for 2 hr to assess the basal glucose turnover. After the basal period,
hyperinsulinemic-euglycemic clamp was conducted for 120 min
with a primed/continuous infusion of human insulin (25 mU/kg
prime for 5 min, 5 mU/kg/min infusion) and variable infusion of
20% glucose to maintain euglycemia (approximately 100 mg/dl).
The 20% glucose was enriched with [6,6-
2H] glucose to
approximately 2.5% as previously described [12]. To determine
the enrichment of [6,6-
2H]glucose in plasma at basal and insulin
stimulated state, samples were deproteinized with trichloroacetic
acid and derivatized with p-aminobenzoic acid ethyl ester. The
atom percentage enrichment of glucosem+2 was then measured by
high-performance liquid chromatography with LTQ-XL-Orbitrap
mass spectrometer (Thermo Scientific, CA). The glucosem+2
enrichment was determined from the m/z ratio 332.2: 330.2. The
hepatic glucose production was calculated by using the rate of
infusion of [6,6-
2H]glucose over the atom percent excess in the
plasma minus the rate of glucose being infused. The insulin-
stimulated whole-body glucose uptake was calculated by adding the
total glucose infusion rate plus the hepatic glucose production [12].
Quantitative real-time PCR. Quantitative real-time PCR
was performed as described [9]. Total RNA was prepared using
Sepazol (Nacalai Tesque, Kyoto, Japan). cDNA was synthesized
from 5 mg of total RNA using Superscript II reverse transcriptase
(Invitrogen Inc., Carlsbad, CA) with random primers. Gene
expression levels were measured with an ABI PRISM 7700 using
SYBR Green PCR Core Reagents (Applied Biosystems, Tokyo,
Japan). The primers used were as follows, RXRc: Fw: 59-CAC-
Table 1. Body and dissected tissue weight and blood glucose
level in RXRc mice (4-3 line).
Wild-type RXRc
Body weight (g) 26.460.3 26.560.4
Epididymal fat mass (g) 0.13860.004 0.15660.090
Gastrocnemius muscle weight (g) 0.28260.004 0.23860.008**
Liver weight (g) 1.29060.029 1.32160.033
Glucose (mg/dL) basal 170.069.4 145.664.9*
Glucose (mg/dL) fasting 74.461.7 67.060.6**
Mice were males 12 weeks of age. The number of animals used was 6 for both
wild-type control and RXRc mice.
* P,0.05;
** P,0.01, compared with wild-type control.
Values are the means 6 SE. These samples were also used in Fig 2A, B, and D.
doi:10.1371/journal.pone.0020467.t001
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CTGTTCC-39, Glut1: Fw: 59-CCAGC TGGGA ATCGT CG-
TT-39, Rv: 59-CAAGT CTGCA TTGCC CATGAT-39, Glut4:
Fw: 59-TCTGTGGGTGGCATGATCTCT-39, Rv: 59-GCCCT-
TTTCCTTCCCAACC-39, glucose phosphate isomerase 1: Fw:
59-AGCGCTTCAACAACTTCAGCT-39, Rv: 59-CAGAATAT-
GCCCATGGTTGGT-39, phosphoglycerate mutase 1: Fw: 59-
TCCTGAAACATCTGGAAGGTATCTC-39, Rv: 59-CAGTG-
GGCAGAGTGATGTTGAT-39, fructose bisphosphatase 2: Fw:
59-TGAATGCAATCCTGTGGCC-39, Rv: 59-TGGTTGCCA-
TACCTCCTGCT-39, pyruvate dehydrogenase kinase isoenzyme
1: Fw: 59-GGACTTCTATGCGCGCTTCT-39, Rv: 59-CTGA-
CCCGAAGTCCAGGAAC-39, glycogen synthase 2: Fw: 59-AG-
GATCATTCAGAGGAACCGC-39, Rv: 59-CCAGTCCAGGA-
GATCTGAGAGC-39.
Tissue sampling for analysis of Glut1 and Glut4 protein
levels
Skeletal muscles were homogenized in ice-cold buffer
containing 250 mmol/L sucrose, 20 mmol/L 2-[4-(2-hydro-
xyethyl)-1-piperadinyl] ethonsulforic acid (HEPES) (pH 7.4),
and 1 mmol/L EDTA, and centrifuged at 1200 g for 5
minutes. The supernatant was centrifuged at 200 000 g for 60
minutes at 4uC [13]. The resulting pellet was solubilized in
Laemmli sample buffer containing dithiothreitol. Samples were
subjected to Western blotting as described [14]. Antibodies
used were those against Glut1 (#07-1401, Millipore, Temecula,
CA), and Glut4 (SC-1606, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA).
Muscle incubation and glucose transport
Glucose transport was measured as described [15]. Mice were
fasted overnight and killed. The extensor digitorum longus (EDL)
muscles were rapidly removed, each of which was mounted on the
incubation apparatus and preincubated in Krebs-Ringer bicarbon-
ate (KRB) buffer containing 2 mmol/l pyruvate for 30 min. The
muscles were then incubated in KRB buffer in the absence or
presence of 50 mU/ml insulin for 10 min. The buffers were kept at
37uC throughout the experiment and gassedcontinuously with 95%
O2 and 5% CO2. Immediately after incubation, the muscle was
transferred to KRB buffer containing 1 mmol/l 2-[
3H]-deoxy-d-
glucose (1.5 mCi/ml) and 7 mmol/l d-[
14C]-mannitol (0.3 mCi/ml).
Figure 1. Glucose tolerance and insulin tolerance tests on RXRc mice. (A, B) In A and B, male mice, 5 months of age, were used. The number
of animals used was 6 for both control (open circles) and RXRc (filled circles) mice of line 4-3, and 5 for both control (open circles) and RXRc (filled
circles) mice of line 5-3. * P,0.05 and ** P,0.01 compared with respective control.
doi:10.1371/journal.pone.0020467.g001
Table 2. Body and dissected tissue weight and blood glucose
level in RXRc mice (5-3 line).
Wild-type RXRc
Body weight (g) 36.061.8 31.961.2
Epididymal fat mass (g) 1.03060.191 0.86160.134
Gastrocnemius muscle weight (g) 0.30560.016 0.21460.020**
Liver weight (g) 1.37560.119 1.32060.066
Glucose (mg/dL) basal 142.568.6 117.368.2
Glucose (mg/dL) fasting 67.261.6 53.362.5**
Mice were males 38 weeks of age. The number of animals used was 6 for both
wild-type control and RXRc mice.
** P,0.01, compared with wild-type control.
Values are the means 6 SE.
doi:10.1371/journal.pone.0020467.t002
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The skeletal muscle glycogen content was measured as
glycosyl units after acid hydrolysis [16]. The skeletal muscle
samples were minced, 50 mg of which was added to 1 ml of
0.3 M percholic acid and homogenized on ice. One ml of 1 N
HCl was added and incubated for 2 h at 100uC, thereafter, 1 ml
of 1 N NaOH was added at room temperature. Glucose content
w a se x a m i n e du s i n gt h eF - k i tg l u c o s e( R o c h eD i a g n o s t i c s ,
Mannheim, Germany).
Plasmids
The coding region of mouse RXRc and PPARd cDNA were
subcloned into a mammalian expression plasmid, pCMX [9]. The
1.5-kb 59-flanking region of the mouse Glut1 promoter was
obtained by PCR with mouse genomic DNA (RefSeqs number:
NC_000070). The PCR primers used were: Fw: 59-GTGGTG-
CGCGCCTGTAGTCC-39 and Rv: 59-GGCGCACTCCACG-
GATGCCG-39. The fragment was subcloned into the pGL3-basic
luciferase vector (Promega Corporation, Madison, WI). The
promoter regions used were: -1500 to +75, -647 to +75, and
-152 to +75, counting the transcription start site as +1.
Electroporation and in vivo luciferase reporter analysis
In vivo electroporation was performed according to the modified
method of Aihara and Miyazaki [17]. Under the pentobarbital
anesthesia (30 mg/kg), bilateral quadriceps muscles from C57BL6
Figure 2. Levels of Glut 1 and Glut4, and glucose uptake in the skeletal muscle of RXRc mice. (A) Gene expressions of RXRc, Glut1, and 4
were examined by quantitative real-time PCR. The value for wild-type (littermates of line 4-3) mice was set at 100, and relative values are shown. (B)
Protein levels of Glut1 and Glut4 were examined by Western blotting. Results of relative densitometric signal for Glut1 and 4 are shown. (C) Glucose
uptake in the absence or presence of insulin and (D) glycogen content were increased in the skeletal muscle of RXRc mice. Ratio of enhanced glucose
uptake in the presence of insulin (insulin/basal) was similar in control and RXRc mice. In A, B and D, the same samples were used. Mice were males of
12 weeks of age. The number of animals was 6 for both control (open bars) and RXRc (filled bars) mice. These samples were also used in Table 1. In C,
mice were males of 24–27 weeks of age. The number of animals was 6 for both control (open bars) and RXRc (filled bars) mice. * P,0.05 and
** P,0.01 compared with respective control. N. S., not significant.
doi:10.1371/journal.pone.0020467.g002
Table 3. Body weight, blood glucose and plasma insulin
levels in RXRc mice in clamp study.
Wild-type RXRc
Body weight (g) 24.161.2 23.460.3
Basal period Glucose (mg/dL) 141.8615.3 106.665.5*
Insulin (ng/mL) 0.5560.08 0.4460.07
Clamp period Glucose (mg/dL) 92.563.8 96.763.6
Insulin (ng/mL) 2.6060.20 2.3860.33
Mice were males 13–16 weeks of age. The number of animals used was 6 for
wild-type control mice and 7 for RXRc mice.
* P,0.05, compared with wild-type control.
Values are the means 6 SE. These mice were also used in Fig 3.
doi:10.1371/journal.pone.0020467.t003
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DNA (25 ml) by using a 29-gauge needle attached to a 0.5-ml
insulin syringe (Terumo Corporation, Tokyo, Japan). Square-wave
electrical pulses (160 V/cm) were applied six times with an
electrical pulse generator (CUY21EDIT, Nepa Gene Co. Ltd.,
Chiba, Japan) at a rate of one pulse per second, with each pulse
being 20 ms. in duration. The electrodes were a pair of stainless
steel needles inserted into the quadriceps muscles and fixed 5 mm
apart. Seven days after gene delivery, the muscles were removed
and subjected to analysis. Frozen muscle tissues were homogenized
in ice-cold passive lysis buffer from Promega. The homogenate
was centrifuged at 10,000 g for 10 min at 4uC. The supernatant
was reserved for luciferase assay using Promega’s dual luciferase
assay kit. The luciferase activity was calculated as the ratio of
firefly to Renilla (internal control) luciferase activity and
represented as the average of triplicate experiments.
Computer-based DNA sequence motif search
We used MATCH software [18] (BIOBASE GmbH, Wolfen-
buettel, Germany) to investigate transcriptional binding sites in the
mouse Glut1 promoter. We investigated mouse genome in the
region of -1500 to +100 relative to transcription start of Glut1
(Chr.4 11878131(+)).
cDNA microarray analysis
RNA was isolated from the skeletal muscle of sex- and age-
matched RXRc mice (line 4-3) and non-transgenic control mice
Figure 3. Hyperinsulinemic-euglycemic clamp test in RXRc mice, fed a chow diet. (A) Basal glucose disposal rate, (B) glucose infusion rate
needed to maintain euglycemia, (C) insulin-stimulated glucose disposal rate and (D) clamp hepatic glucose production (hepatic glucose production
during the clamp period) (E) suppression of hepatic glucose production during the clamp period in RXRc mice. Male mice, 13,16 weeks of age, were
used. The number of animals used was 6 for control mice (open bars) and 7 for RXRc mice (filled bars). * P,0.05 and ** P,0.01 compared with
respective control. N. S., not significant.
doi:10.1371/journal.pone.0020467.g003
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combined). Each of the combined samples was hybridized to the
Affymetrix MG430 microarray, which contains 45,102 genes,
including expressed sequence tags (ESTs), and analyzed with the
software Affymetrix Gene Chip 3.1. Of the 45,102 genes including
ESTs analyzed, 8,054 (non-transgenic control mice) and 8,083
(transgenic) were expressed at a substantial level (absolute call is
present and average difference is above 150). In order of fold
changes in gene expression levels in skeletal muscle from RXRc
mice relative to control mice, genes whose expression was
increased more than 2
0.4-fold in RXRc mice were listed (Dataset
S1). Fold changes were calculated as an indication of the relative
change of each transcript represented on the probe array.
Differentially expressed genes were identified using the following
criteria; ‘absolute call’ is present, and ‘average difference’ was
above 250. ‘Absolute call’, which was calculated with this software
using several markers, is an indicator of the presence or absence of
each gene transcript. The ‘average difference’ value is a marker of
the abundance of each gene, obtained by comparing the intensity
of hybridization to 20 sets of perfectly matched 25-mer
oligonucleotides relative to 20 sets of mismatched oligonucleotides
using Affymetrix Gene Chip 3.1 software. All data of microarray is
MIAME compliant and that the raw data has been deposited in a
MIAME compliant database (GEO), whose accession number is
GSE28448.
Gene Ontology Analysis
We used DAVID v6.7 [19] for gene ontology (GO) analysis.
DAVID is a web application providing a comprehensive set of
functional annotation tools to understand the biological meaning
behind a large list of genes. Functional Annotation Clustering of
DAVID was applied to the genes whose gene expression increased
in RXRc mice. Our GO analysis produced 62 GO terms from
gene sets from RXRc mice with increased expression compared to
the wild-type mice, under the condition of P,0.05 (P value from
Fisher’s Exact Test). The obtained GO terms contained many
similar functional concepts. In order to group similar GO terms,
we applied the Functional Annotation Clustering tool provided by
DAVID [19,20]. Twenty-three clusters were produced with genes
showing increased expression. We showed one GO term of the
lowest P value of all the members of an individual cluster.
Transcriptional factor binding sites analysis
We used MATCH software [18] with BKL TRANSFAC
2010.3 Release (BIOBASE GmbH, Worfenbuettel, Germany) to
investigate transcriptional binding sites in the promoter regions of
genes. The F-Match algorithm compares the number of sites
found in a query sequence set against the background set. It is
assumed, if a certain transcription factor (or factor family), alone or
as a part of a cis-regulatory module, plays a significant role in the
regulation of the considered set of promoters, then the frequency
of the corresponding sites found in these sequences should be
significantly higher than expected by random chance. We
investigated the mouse genome in the region of -1000 to +100
relative to the transcription start of an individual gene. Statistical
hypothesis testing was evaluated against housekeeping genes of
mice. We investigated promoter regions of 15 genes: that is 14
‘glucose metabolic process’ genes with increased expression in
RXRc mice, plus Glut1. In the GO analysis, Glut1 was
categorized as a ‘transporter’ not ‘glucose metabolic process’ gene.
Statistical analysis
Statistical analysis was performed using the Student’s t test and
analysis of variance (ANOVA) followed by Scheffe’s test. Data
were expressed as the mean 6 SE. P,0.05 was considered
statistically significant.
Results
Increased glucose metabolism in RXRc mice
In our previous study, we established two lines of RXRc mice
(named lines 4-3 and 5-3) with similar expression levels of the
RXRc transgene and protein specifically in the skeletal muscle [9].
There was no significant difference in body weight, adipose tissue,
Figure 4. Transient transfection-reporter assay of the effect of RXRc on Glut1 promoter. (A) Glut1-Luc plasmid, with or without RXRc and/
or PPARd expression vectors, was transfected into the quadriceps muscle of C57BL6 mice. Activation of the luciferase reporter gene was measured in
relative light units and normalized to dual luciferase activity. Mean values from experiments (n=5) are shown as fold induction, where the activity in
the absence of RXRc is the reference value (set at 100). (B) Schematic representations of serial deletion of Glut1 promoter constructs are shown in the
figure. Squares denote the putative PPAR/RXR binding sites. Open bars; Glut1-Luc without RXRc and PPARd expression vectors, and filled bars; Glut1-
Luc with RXRc and PPARd expression vectors. The activity in the absence of RXRc and PPARd in each experiment for different Glut1-Luc construct in
the reference value (set at 100). ** P,0.01, compared with the value of wild-type promoter in the absence of RXRc/PPARd.
doi:10.1371/journal.pone.0020467.g004
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and 5-3, although the skeletal muscle weight was slightly lower in
RXRc mice than in control mice (Tables 1 and 2). In this study,
blood glucose in RXRc mice was lower than in control mice
(fasting state, P,0.01 in lines 4-3 and 5-3; basal state, P,0.05 in
line 4-3 and P=0.06 in line 5-3), which is consistent with our
previous report [9].
To elucidate the role of the skeletal muscle RXRc in systemic
glucose metabolism, we performed glucose and insulin tolerance
tests in RXRc mice. The glucose tolerance test revealed increased
glucose disposal in RXRc mice relative to control mice (Fig. 1A).
On the other hand, there was no significant difference in the
insulin-induced hypoglycemic response between genotypes
(Fig. 1B). These observations suggest that RXRc mice have a
higher capacity for glucose disposal with no change in insulin
sensitivity.
Increased Glut1 expression and glucose uptake in the
skeletal muscle of RXRc mice
As both lines of RXRc mice showed increased glucose
metabolism, for the following experiments, we only utilized the line
4-3 of RXRc mice (hereafter just RXRc mice). Interestingly,
mRNAexpression of Glut1 was increased inthe skeletalmuscle from
RXRc mice relative to control mice (P,0.01), whereas that of Glut4
was unchanged (Fig. 2A). We also observed that Glut1 is
significantly increased in RXRc mice at the protein level
(P,0.05), with no significant difference in Glut4 between genotypes
(Fig.2B).Consistently,wealsofoundincreasedglucoseuptakeinthe
skeletal muscle from RXRc mice relative to control mice (P,0.05),
which was not further enhanced in the presence of insulin (Fig. 2C).
We also observed increased glucose glycogen content in the skeletal
muscle from RXRc mice relative to control mice (P,0.05, Fig. 2D).
Increased basal glucose disposal rate of RXRc mice
To gain further insight into the glucose metabolism in RXRc
mice, we performed a hyperinsulinemic-euglycemic clamp study.
Plasma insulin concentrations during the basal period were similar
between genotypes (Table 3). The basal glucose disposal rate was
significantly increased in RXRc mice than in the controls
(P,0.05, Fig. 3A), supporting that an insulin-independent increase
in glucose uptake occurred, as observed in Fig. 2C. Meanwhile, we
observed that the rate of glucose infusion needed to maintain
euglycemia (glucose infusion rate) was similar between genotypes
(Fig. 3B), which is consistent with the result of the insulin tolerance
test (Fig. 1B). On the other hand, insulin-stimulated glucose
disposal rate was higher in RXRc mice than in the controls
(P,0.01, Fig. 3C), which probably reflects the increased basal
glucose disposal rate (Fig. 3A). Also, the clamp hepatic glucose
production (hepatic glucose production during the clamp period)
was higher in RXRc mice than in the controls (P,0.05, Fig. 3D).
Meanwhile, hepatic glucose production was similarly suppressed
by insulin in both genotypes (Fig. 3E). Together, these data
support the idea that Glut1, an insulin-independent glucose
transporter, is involved in the increased glucose disposal in the
skeletal muscle of RXRc mice.
Activation of the Glut1 promoter by combination of RXRc
and PPARd in the skeletal muscle in vivo
To examine whether RXRc directly activates mRNA expres-
sion of Glut1, we performed the in vivo luciferase reporter analysis
Table 4. Gene Ontology Analysis.
GO ID GO Term P value
GO:0060537 muscle tissue development 6.91E-05
GO:0006461 protein complex assembly 6.78E-05
GO:0008104 protein localization 1.18E-04
GO:0051146 striated muscle cell differentiation 6.06E-04
GO:0030334 regulation of cell migration 8.04E-04
GO:0006886 intracellular protein transport 0.002367379
GO:0019220 regulation of phosphate metabolic process 0.00312153
GO:0048514 blood vessel morphogenesis 0.00172443
GO:0045859 regulation of protein kinase activity 0.00563927
GO:0006915 apoptosis 0.007513423
GO:0006006 glucose metabolic process 0.002958786
GO:0006917 induction of apoptosis 0.005257921
GO:0042981 regulation of apoptosis 0.014518039
GO:0043066 negative regulation of apoptosis 0.022995692
GO:0006633 fatty acid biosynthetic process 0.012664127
GO:0032956 regulation of actin cytoskeleton organization 0.027565775
GO:0043388 positive regulation of DNA binding 0.021966247
GO:0006469 negative regulation of protein kinase activity 0.045894089
GO:0016477 cell migration 0.045248711
GO:0030521 androgen receptor signaling pathway 0.027402985
GO:0055003 cardiac myofibril assembly 0.020081231
GO:0000165 MAPKKK cascade 0.032045331
GO:0046825 regulation of protein export from nucleus 0.027402985
738 genes up-regulated in RXRc mice compared with wild-type mice by
microarray (Listed in Dataset S1) were classified into GO functional annotations,
as described in Methods.
doi:10.1371/journal.pone.0020467.t004
Table 5. List of ‘glucose metabolic process’ genes.
Gene Symbol Gene description
Atf3 Activating transcription factor 3
Bpgm 2-3-bisphosphoglycerate mutase
Dcxr Dicarbonyl L-xylulose reductase
Fbp2 Fructose bisphosphatase 2
Gbe1 Glucan branching enzyme 1
Gpd1l Glycerol-3-phosphate dehydrogenase 1-like
Gpi1 Glucose phosphate isomerase 1
Gys2 Glycogen synthase 2
Igf2 Insulin-like growth factor 2
Mat2b Methionine adenosyltransferase II, beta
Nisch Nischarin; an imidazoline receptor
Pdk1 Pyruvate dehydrogenase kinase isoenzyme 1
Pgam1 Phosphoglycerate mutase 1
Pgd Phosphogluconate dehydrogenase
Pgm2l1 Phosphoglucomutase 2-like 1
Phkb Phosphorylase kinase beta
Up-regulated genes in RXRc mice in the microarray, classified as ‘glucose
metabolic process’ genes by GO analysis, as described in Method. Genes are
listed in alphabetic order of gene symbol. Glut1, which appeared in the up-
regulated list in the microarray (Dataset S1), is not included in this list, as it was
classified ‘transporter’ in the GO analysis.
doi:10.1371/journal.pone.0020467.t005
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Glut1-Luc was marginally enhanced by RXRc alone (Fig. 4A).
Moreover, we found no significant activation of the Glut1-Luc by
PPARd, an important regulator of glucose as well as lipid
metabolism in the skeletal muscle [7]. Interestingly, combination
of RXRc and PPARd resulted in significant increase in Glut1-Luc
activity in the skeletal muscle in vivo (P,0.01) (Fig. 4A). Motif
search analysis revealed two putative PPAR-responsive elements
(PPRE1 and PPRE2) (2657/2645 and 2520/2508, respectively)
in the mouse Glut1 promoter. A series of deletion mutant analysis
showed that combination of RXRc and PPARd activates the
regions of 21500/+75, and 2647/+75, but not the region of
2152/+75 in the Glut1 promoter (Fig. 4B), suggesting that the
second putative PPRE (2520/2508) is involved in the RXRc/
PPARd-induced Glut1 promoter activation.
Microarray and bioinformatics analyses of up-regulated
gene in RXRc mice
In order to gain insight into the gene expression change in
RXRc mice, we performed microarray analysis. As shown in
Dataset S1, 738 genes were up-regulated in the analysis. As
expected, Glut1 expression was increased in the microarray data.
Also, SREBP1c expression, which we previously reported [9], was
increased in the microarray data. Using the data, we performed
GO analysis to determine if genes, up-regulated in RXRc mice,
are associated with particular biological processes. Our GO
analysis revealed genes with increased expression in the RXRc
mice in various categories (Table 4), including ‘glucose metabolic
process’ genes and ‘fatty acid biosynthetic process’ genes, which
indicated that overexpression of RXRc affects the expression of
many genes. The up-regulated genes categorized as glucose
metabolism genes in GO term are listed in Table 5. Among them,
we confirmed enhanced gene expression by quantitative real time
PCR (Fig. 5), supporting the microarray data reliable. Moreover,
we calculated the ratio of putative transcription factor binding
motifs in glucose metabolism genes, which were up-regulated in
RXRc mice. In the sample, several motifs showed statistical
significance (Table 6) (P,0.05), including PPAR responsive
elements. These data suggest that glucose metabolism genes up-
regulated in RXRc mice are possible target genes of the RXRc
and PPAR heterodimer.
Discussion
RXRc is a nuclear receptor-type transcription factor that is
expressed abundantly in the skeletal muscle and is regulated by
nutritional conditions. Treatment of obese and diabetic mice with
RXR pan-agonists (agonists for all the RXR isoforms) has
improved glucose metabolism in mice [21–23], suggesting the
beneficial effect of RXR on diabetes. However, which RXR
isoform(s) are involved and where they work to improve diabetes
Figure 5. Levels of ‘glucose metabolic process’ gene expression in the skeletal muscle of RXRc mice. Representative gene expressions of
‘glucose metabolic process genes’ analyzed by microarray and GO analysis (Table 5) were examined by quantitative real-time PCR. The value for wild-
type (littermates of line 4-3) mice was set at 100, and relative values are shown. Mice were females of 4 months of age. The number of animals was 6
for both control (open bars) and RXRc (filled bars) mice. These samples were also used in microarray analysis (Dataset S1). * P,0.05 and ** P,0.01
compared with respective control. N. S., not significant.
doi:10.1371/journal.pone.0020467.g005
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in RXRc mice.
We demonstrated increased glucose metabolism in RXRc mice
relative to control mice, although there was no significant
difference in the insulin-induced hypoglycemic effect between
genotypes, based on insulin tolerance test and glucose clamp
analysis. Because insulin level is similar between RXRc mice and
control mice, it is unlikely that increased insulin secretion is
responsible for increased glucose tolerance in RXRc mice. On the
other hand, mRNA and protein expression of Glut1 is increased in
the skeletal muscle from RXRc mice relative to control mice, with
increased glucose uptake and glycogen content. Because trans-
genic overexpression of Glut1 in the skeletal muscle has resulted in
increased glucose uptake [24], glycogen content [25] and lowering
of blood glucose [24], it is likely that enhanced glucose tolerance in
RXRc mice is mediated at least in part by increased Glut1 in the
skeletal muscle.
As RXRc is a nuclear receptor-type transcription factor that
heterodimerizes with many nuclear receptors [6], we examined
whether the Glut1 gene is directly regulated by RXRc.I na nin vivo
luciferase reporter analysis, combination of RXRc and PPARd
activates the Glut1 promoter activity, which is diminished by
deletion of the putative PPREs. It is, therefore, RXRc/PPARd may
activate Glut1 expression in the skeletal muscle in vivo. In this regard,
we found that overexpression of RXRc or PPARd alone or both in
C2C12 myocytes in vitro does not induce Glut1 gene expression
(unpublished data). This may be because C2C12 cells lack other
factor(s) that are present in the skeletal muscle in vitro and are
required toactivateGlut1transcription.WhethertheincreasedGlut1
gene in RXRc mice is mediated by RXRc/PPARd should be
confirmed by additional experiments using PPARd knockout mice.
Meanwhile, the transgene expression level in RXRc mice was very
high, and appeared to be beyond the physiological level.
Nonetheless, if RXRc can be enhanced in skeletal muscle, an
increase in glucose metabolism can be expected.
We recently demonstrated that in addition to glycogen content,
RXRc mice exhibit increased triglyceride in the skeletal muscle as
a result of increased SREBP1c gene expression [9]. In obese and
diabetic subjects, intramuscular lipid is high with insulin resistance
[26]. Moreover, in athletes, the skeletal muscle is also high in lipid
but with high insulin sensitivity, which is known as the athlete
paradox [27,28]. A partial explanation is an increased fatty acid
load in obese and diabetic subjects, but not in athletes; increased
intramuscular lipotoxic fatty acid metabolites, such as diacylgly-
cerol and ceramide, cause insulin resistance in skeletal muscles
[29,30]. Taken together with our previous report [9], this study
demonstrates that RXRc mice do not develop insulin resistance
despite high intramuscular lipids, and appear to be protected
against obesity-induced lipotoxicity in the skeletal muscle.
Depositing glucose as both glycogen and triglycerides in the
skeletal muscle may be effective in enhancing glucose metabolism.
Microarray analysis showed that various genes are up-regulated
in the skeletal muscle of RXRc mice. As RXRc can hetero-
dimerize several nuclear receptors, it is not surprising that
expression of many genes was up-regulated by RXRc overex-
pression. Concerning glucose metabolism genes, in the skeletal
muscle of RXRc mice, the expression levels of genes, such as
glucose phosphate isomerase 1 and phosphoglycerate mutase 1
(stimulate glycolysis or gluconeogenesis), fructose bisphosphatase 2
(stimulates gluconeogenesis), pyruvate dehydrogenase kinase
Table 6. Possible transcription factor binding sites in the ‘glucose metabolic process’ gene up-regulated in RXRc mice.
Transcription factors Matrix name P-value
WT1, WT1 -KTS, WT1 I, WT1 I -KTS WT1_Q6 6.98E-04
HNF-4, HNF-4alpha HNF4ALPHA_Q6 0.0013
PPARalpha PPARA_01 0.0017
c-Myb, c-Myb-isoform1 VMYB_02 0.0026
PPARalpha, PPARdelta, PPARgamma PPAR_DR1_Q2 0.003
CART1, CART1, CART1 CART1_01 0.0036
COUP-TF1, COUP-TF2, HNF-4, HNF-4alpha COUP_DR1_Q6 0.0036
CP2, CP2-isoform1 CP2_02 0.0055
NRF1-isoform1, NRF1-isoform2, NRF1-xbb1 TCF11_01 0.0057
SZF1 SZF11_01 0.0057
PPARgamma PPARG_01 0.0057
COUP-TF1, COUP-TF2, HNF-4, HNF-4alpha, HNF4gamma DR1_Q3 0.0057
BRCA1, BRCA1 BRCA_01 0.0065
HNF-3beta HNF3B_01 0.007
Pax-2b, pax2 PAX2_01 0.007
C/EBPalpha, C/EBPbeta(LAP), C/EBPbeta(p20), C/EBPbeta(p20), C/EBPbeta(p34),
C/EBPbeta(p35), C/EBPgamma, cebpe, CRP3, NF-IL6-1, NF-IL6-3
CEBP_Q3 0.007
MITF, MITF-M1, tcfec, TFEA, TFEA-xbb1, TFEA-xbb2, tfeb, tfeb-isoform1 TFE_Q6 0.007
AP-2alpha, AP-2beta, AP-2gamma AP2_Q6_01 0.0077
Pax-4a, Pax-4c, Pax-4d, Pax4 PAX4_04 0.0079
c-Myc, deltaMax, max, max-isoform1, max-isoform2, N-Myc MYCMAX_03 0.0093
The mouse genome in the region of 21000 to +100 relative to the transcription start of an individual gene classified as glucose metabolism gene by GO analysis
(Table 5), was analyzed. Statistical hypothesis testing was evaluated against housekeeping genes of mice. Matrics names are based on the MATCH software (see
Methods), which are listed in P-value order. Indicated binding sites of transcription factors appeared significantly more frequent occurrence in the promoter sets.
doi:10.1371/journal.pone.0020467.t006
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glycogen synthesis)[31,32], were markedly increased (Fig. 5),
suggesting the anabolic reaction of glucose. This is consistent with
the observation that the glycogen content of skeletal muscle is
higher in RXRc mice (Fig. 2C). It is of note that glycogen synthase
2 is a liver-type enzyme, not a skeletal muscle-type enzyme [32]. In
addition, usually, gluconeogenesis is not considered to be a major
metabolic pathway in skeletal muscle. Chronic transgenic
overexpression of RXRc may have caused a super-physiological
gene expression change in the skeletal muscle. Meanwhile, our
bioinformatics analysis showed that glucose metabolism genes up-
regulated in RXRc mice contain several transcription factor
binding motifs including PPRE in their promoter region. These
observations support the concept that the RXRc/PPAR hetero-
dimer contributes to activation of these gene sets, although this
needs to be confirmed by further experiments.
In summary, we demonstrated enhanced glucose metabolism
with increased Glut1 expression and glucose uptake in RXRc mice.
Thisstudysuggested thatactivationoftheskeletalmuscleRXRcisa
novel therapeutic strategy to treat or prevent type 2 diabetes.
Supporting Information
Dataset S1 List of genes up-regulated in RXRc mice
compared with wild-type control mice by microarray.
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